Chemicals · NSE: ANURAS
Anupam Rasayan India
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 6 Nov 2026 · Read the filing on NSEFiling
- M.Cap
- ₹14,992Cr
- P/E
- 83.1×
- 1Y return
- +22.70%
- From 52W high
- −6.9%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 806 | 731 | +10.2% | 655 | +23.0% |
| EBITDA | 187 | 136 | +37.9% | 162 | +15.3% |
| EBITDA margin | 23.2% | 18.6% | +466 bps | 24.8% | -156 bps |
| PBTProfit before tax | 89 | 76 | +18.4% | 70 | +28.4% |
| Net profit | 50 | 44 | +12.7% | 39 | +29.5% |
| EPS (₹) | 4.39 | 3.93 | +11.7% | 3.39 | +29.5% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
Margin guidance kept unchanged despite higher recent standalone margins
Vishal Thakkar · Advisor · Q&A · p. 8
Margin guidance kept unchanged despite higher recent standalone margins
“I would urge to caution and continue to guide at the numbers that we have been guiding.”
More figures from the call
“Even if I take a run rate, you can double the run rate from there over the next year to year and a half per month.”
“So if I do a six to seven years, the number will be around about INR2,500 odd crores on an average, of which last year we did around about INR350 odd crores”
In short
- 01H2 FY27 consolidated revenue guided at about Rs 2,400-2,500 crore, as all four businesses get consolidated.
- 02Annualised revenue run rate seen at about Rs 4,800-5,000 crore, then 20-25% organic growth over three to five years.
- 03Bliss GVS Pharma acquisition completed on 28 September 2026; Anupam now holds about 50.07%.
- 04Bliss deal funded by a Rs 300 crore term loan and a Rs 1,450 crore non-voting instrument led by Bain Capital.
- 05Bliss steady-state EBITDA margin guided at 22%-24%; company keeps its existing margin guidance despite higher margins.
- 06LOIs and long-term contracts stand at about Rs 17,496 crore; contract revenue this year seen at 1.8x-2x last year's Rs 350 crore.
- 07New six-year contract with a US specialty metal maker; Rs 100-150 crore expected this year.
- 08Q2 FY27 consolidated EBITDA margin 25% versus 19% a year ago, driven by Performance Materials and product mix.
Capacity
Bliss GVS: Bliss plant utilisation in the 40s
Vishal Thakkar · Advisor · Q&A · p. 9
Bliss GVS: Bliss plant utilisation in the 40s
“Their utilizations will be in the 40s, because if you see, they have a very meaningful growth from the last year.”
Company keeps some capacity free to win new customers
Vishal Thakkar · Advisor · Q&A · p. 12
Company keeps some capacity free to win new customers
“Our strategy of keeping a level of capacity free really helps us in terms of attracting this customer well.”
Order book
Cumulative LOIs and long-term contracts stand at about Rs 17,496 crore
Anand Desai · Managing Director · p. 3
Cumulative LOIs and long-term contracts stand at about Rs 17,496 crore
“Our cumulative portfolio of LOIs and long-term contracts now stands at approximately INR17,496 crores, providing visibility over multiple years.”
geological resources: US specialty metal supply deal marks entry into new geological resources segment
Anand Desai · Managing Director · p. 4
geological resources: US specialty metal supply deal marks entry into new geological resources segment
“This marks our entry into a new segment within the geological resources sector and represents an important step in diversifying our customer base and expanding our presence in specialized industrial applications.”
specialty metal: Specialty metal customer converted into a six-year contract within four months
6yearsVishal Thakkar · Advisor · Q&A · p. 12
specialty metal: Specialty metal customer converted into a six-year contract within four months
6years“In a matter of just four months' time from start to now, we have been able to convert them into a six-year long-term contract”
specialty metal: Specialty metal product commercialised in four months; supply starts from November
Vishal Thakkar · Advisor · Q&A · p. 12
specialty metal: Specialty metal product commercialised in four months; supply starts from November
“We did it in four months. We could do a commercialization of this product, and we are starting to supply from November itself.”
Elementium: Elementium contract talks ongoing, expected to conclude soon; monthly supplies started
Vishal Thakkar · Advisor · Q&A · p. 14
Elementium: Elementium contract talks ongoing, expected to conclude soon; monthly supplies started
“The second point on the Elementium side, the contract discussions are right now ongoing, and we believe that we should be able to come out, conclude this soon. On the supply side, we started supplying some volumes to our customers on the schedule on a monthly basis.”
Segments
Q2 revenue mix: life science 42%, Performance Materials 28%, other fluorinated 29%
Hetvi Vyas · Deputy Chief Financial Officer · p. 6
Q2 revenue mix: life science 42%, Performance Materials 28%, other fluorinated 29%
“Revenue breakup for Q2FY27 was as follows: Life science-related specialty chemicals contributed 42%, Performance Materials contributed 28%, other fluorinated products contributed 29%.”
Bliss CDMO: Bliss CDMO discussions have picked up momentum
Vishal Thakkar · Advisor · Q&A · p. 8
Bliss CDMO: Bliss CDMO discussions have picked up momentum
“To that extent, yes, the momentum has picked up here. I can say that for now. And we see a very strong growth potential going forward.”
polymer: Polymers make up 20%-25% of revenue
Vishal Thakkar · Advisor · Q&A · p. 10
polymer: Polymers make up 20%-25% of revenue
“If you look at from a polymer side, we have built up a good portfolio. Today, 20%-25% of our revenue comes from that end market.”
pharma KSMs: About 20%-25% of revenue comes from pharma KSMs; Bliss adds formulations
Vishal Thakkar · Advisor · Q&A · p. 10
pharma KSMs: About 20%-25% of revenue comes from pharma KSMs; Bliss adds formulations
“Two, Anupam today has around about 20%, 25% of our revenue coming from KSMs of pharma industry, and Bliss is from the formulation side.”
Bliss GVS: Bliss business has little seasonality, as far as management knows
Vishal Thakkar · Advisor · Q&A · p. 15
Bliss GVS: Bliss business has little seasonality, as far as management knows
“What best I know is there is not much of a seasonality, but I think I will leave it for the management of Bliss to make that statement.”
Demand
polymer: Japanese customer eyeing 1,000 tons said it could triple volumes if supplied from Jayhawk
Vishal Thakkar · Advisor · Q&A · p. 10
polymer: Japanese customer eyeing 1,000 tons said it could triple volumes if supplied from Jayhawk
“One of our Japanese customers was looking at doing, let's say, 1,000 tons with us, but the moment we offered that, the moment we had a Jayhawk announcement, they said, "If you can give us material out of Jayhawk, probably we can triple it to the volumes."”
polymers, electronic chemicals, fluorinated products: Management sees continued traction in polymers, electronic chemicals and fluorinated products
Anand Desai · Managing Director · p. 4
polymers, electronic chemicals, fluorinated products: Management sees continued traction in polymers, electronic chemicals and fluorinated products
“We also continue to see encouraging traction across our polymers, electronic chemicals, and other fluorinated products businesses, supported by our technology capabilities and long-standing customer relationships.”
Margins and costs
Consolidated EBITDA margin 25% in Q2 FY27 vs 19%, driven by Performance Materials and mix
Amit Khurana · Chief Financial Officer · p. 6
Consolidated EBITDA margin 25% in Q2 FY27 vs 19%, driven by Performance Materials and mix
“Our consolidated EBITDA margin improved to 25% in Q2 FY27 compared to 19% in the corresponding quarter last year, while H1 margins improved from 26% from 22%. This improvement was primarily driven by a higher contribution from Performance Materials segment and a favorable product mix.”
Bliss GVS: Bliss margins helped by higher-margin products and passing on price rises
Vishal Thakkar · Advisor · Q&A · p. 8
Bliss GVS: Bliss margins helped by higher-margin products and passing on price rises
“So see, there have been sales of products which are of a higher margin. Also they have been able to pass on the price rises and all.”
Inventory held as a shock absorber for customers against market swings
Vishal Thakkar · Advisor · Q&A · p. 13
Inventory held as a shock absorber for customers against market swings
“And this inventory to us is those shock absorbers so that our customers are not exposed to the vagaries of market so sharply every time.”
Sulfuric acid rose from Rs 7 to Rs 45 a kg; supply to customers maintained
Vishal Thakkar · Advisor · Q&A · p. 13
Sulfuric acid rose from Rs 7 to Rs 45 a kg; supply to customers maintained
“Today, if you look at, sulfuric acid has gone from INR7- INR45 a kg, and yet we have been able to deliver products to our customers where they really feel very, very comfortable to do business with us.”
Jayhawk Fine Chemicals: Jayhawk EBITDA margin to be improved through cost optimisation
Gopal Agrawal · Chief Executive Officer · p. 5
Jayhawk Fine Chemicals: Jayhawk EBITDA margin to be improved through cost optimisation
“Moving to Jayhawk Fine Chemicals, we believe we will continue to focus on integrating Jayhawk Fine Chemicals into our global platform and further improving its EBITDA margin through cost optimization initiatives.”
Debt and working capital
About Rs 300 crore debt taken in a wholly owned subsidiary at single-digit cost
Vishal Thakkar · Advisor · Q&A · p. 14
About Rs 300 crore debt taken in a wholly owned subsidiary at single-digit cost
“Two, around INR300 crores is what we have borrowed on our wholly owned subsidiary as debt. The debt pricing is in the single digit, which is similar to what we take debt on our balance sheet.”
Working capital cycle excluding Bliss fell from 276 days to 271 days
Amit Khurana · Chief Financial Officer · p. 6
Working capital cycle excluding Bliss fell from 276 days to 271 days
“If we exclude Bliss GVS balance sheet, we have seen a slight improvement in our overall working capital cycle, which has reduced from 276 days to 271 days.”
H1 FY27 operating cash flow Rs 328 crore vs Rs 334 crore for all of last year
Amit Khurana · Chief Financial Officer · p. 6
H1 FY27 operating cash flow Rs 328 crore vs Rs 334 crore for all of last year
“Compared with the previous full year's operating cash flow of INR334 crores, the operating cash flow generated in H1 FY27 was INR328 crores, driven by stronger profitability and a greater focus on working capital optimization.”
Cash held across entities to support working capital and minor capex
Vishal Thakkar · Advisor · Q&A · p. 12
Cash held across entities to support working capital and minor capex
“This cash will be used to support their working capital as well as small amount of any minor capex if there is any.”
No acquisition debt loaded onto balance sheets of acquired companies
Vishal Thakkar · Advisor · Q&A · p. 12
No acquisition debt loaded onto balance sheets of acquired companies
“we have ensured that we don't load any debt onto the balance sheet of our targets so that they have enough headroom to grow and there is no pressure of servicing the debt there.”
Fund raising
Bliss deal funded by Rs 300 crore term loan and Rs 1,450 crore non-voting instrument led by Bain
Amit Khurana · Chief Financial Officer · p. 5
Bliss deal funded by Rs 300 crore term loan and Rs 1,450 crore non-voting instrument led by Bain
“The transaction was funded through a INR300 crores term loan and a INR1,450 crores raise through a non-controlling and a non-voting instrument from a group of financial investors led by Bain Capital, including Trust Group and Investec.”
About Rs 1,450 crore quasi-equity for Bliss, with a right to buy investors out
Vishal Thakkar · Advisor · Q&A · p. 14
About Rs 1,450 crore quasi-equity for Bliss, with a right to buy investors out
“Around about INR1,450-odd crores is basically quasi-equity financing, where we have a right to buy them out at any given point in time over a reasonably long period of timeframe.”
Acquisitions and new business
Pharmaceuticals: Bliss GVS Pharma acquisition completed on September 28, 2026; Anupam holds about 50.07%
Gopal Agrawal · Chief Executive Officer · p. 4
Pharmaceuticals: Bliss GVS Pharma acquisition completed on September 28, 2026; Anupam holds about 50.07%
“Completion of Bliss GVS Pharma acquisition as on September 28, 2026, marks an important milestone in our journey towards building an integrated pharmaceutical platform. Anupam Rasayan now holds approximately 50.07% of the equity capital of Bliss GVS Pharma.”
Pharmaceuticals: Bliss GVS brings finished dosage formulations and more than 150 brands
Anand Desai · Managing Director · p. 3
Pharmaceuticals: Bliss GVS brings finished dosage formulations and more than 150 brands
“Bliss GVS brings complementary capabilities in finished dosage formulations, a portfolio of more than 150 brands, established manufacturing infrastructure, and an international distribution network.”
API: Company actively looking for API acquisition; nothing to share yet
Vishal Thakkar · Advisor · Q&A · p. 7
API: Company actively looking for API acquisition; nothing to share yet
“We have been evaluating alternatives, and we continue to have conversations. Right now, we have nothing to really share to the public right now. But as and when we have it, we will definitely announce it for now. But yes, we are actively looking for it.”
Bliss GVS: Bliss received one more European regulator product approval
Vishal Thakkar · Advisor · Q&A · p. 9
Bliss GVS: Bliss received one more European regulator product approval
“they have announced one more approval from the European regulator as well of a product.”
Bliss GVS: Bliss synergy benefits expected to start in three to four quarters
Vishal Thakkar · Advisor · Q&A · p. 9
Bliss GVS: Bliss synergy benefits expected to start in three to four quarters
“But let's see, and we believe that in three to four quarters, we should start seeing some benefit out of that, or at least some momentum getting generated from that.”
Management
Bliss GVS: Bliss has a new CEO, Rahul Adakmol, formerly at DRL and Bharat Serums
Vishal Thakkar · Advisor · Q&A · p. 15
Bliss GVS: Bliss has a new CEO, Rahul Adakmol, formerly at DRL and Bharat Serums
“That the team has been the same, but however, that we have got a new CEO, Rahul Adakmol. He is an industry veteran with very strong experience from DRL and Bharat Serums.”
One-offs
standalone: Standalone Q2 revenue fell due to a one-time sale of about Rs 180 crore in Q2 FY26
Hetvi Vyas · Deputy Chief Financial Officer · p. 7
standalone: Standalone Q2 revenue fell due to a one-time sale of about Rs 180 crore in Q2 FY26
“The decline in the standalone revenue for quarter two of FY27 compared to quarter two of FY26 is primarily attributable to one-time sale of approximately INR180 crores in Q2FY26.”
Other
Pharma and Performance Materials: Revenue cyclicality expected to reduce over the next four to eight quarters
Amit Khurana · Chief Financial Officer · p. 5
Pharma and Performance Materials: Revenue cyclicality expected to reduce over the next four to eight quarters
“As the overall contribution from Pharma and Performance Materials increases and becomes a larger share of the group's revenue mix, we expect revenue cyclicality to reduce over the next four to eight quarters.”
Bliss GVS: Bliss contributed only three days to Q2 consolidated results
3daysAmit Khurana · Chief Financial Officer · p. 6
Bliss GVS: Bliss contributed only three days to Q2 consolidated results
3days“Consequently, its contribution to the consolidated results for the quarter ended 30 September 2026 is limited to three days.”
Q2 FY27 total income Rs 821 crore vs Rs 739 crore, up 11%
Hetvi Vyas · Deputy Chief Financial Officer · p. 6
Q2 FY27 total income Rs 821 crore vs Rs 739 crore, up 11%
“Total income for the quarter stood at INR821 crores compared to INR739 crores in the corresponding quarter last year, registering a strong growth of 11% year-on-year.”
Q2 FY27 EBITDA Rs 202 crore vs Rs 144 crore, up 41%
Hetvi Vyas · Deputy Chief Financial Officer · p. 6
Q2 FY27 EBITDA Rs 202 crore vs Rs 144 crore, up 41%
“EBITDA for the quarter stood at INR202 crores compared to INR144 crores in Q2FY26, representing a growth of 41% year-on-year.”
Q2 FY27 profit after tax Rs 65 crore vs Rs 57 crore, up 14%
Hetvi Vyas · Deputy Chief Financial Officer · p. 6
Q2 FY27 profit after tax Rs 65 crore vs Rs 57 crore, up 14%
“Profit after tax for the quarter was INR65 crores compared to INR57 crores in the corresponding quarter last year, registering a growth of 14% year-on-year.”
Sources
- Earnings call transcript, Q2 FY27 Filed 13 Nov 2026 · 16 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

